cochlioquinone a has been researched along with ketanserin in 1 studies
Studies (cochlioquinone a) | Trials (cochlioquinone a) | Recent Studies (post-2010) (cochlioquinone a) | Studies (ketanserin) | Trials (ketanserin) | Recent Studies (post-2010) (ketanserin) |
---|---|---|---|---|---|
13 | 0 | 2 | 3,094 | 335 | 283 |
Protein | Taxonomy | cochlioquinone a (IC50) | ketanserin (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0016 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0021 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
5-hydroxytryptamine receptor 1D | Homo sapiens (human) | 0.265 | |
5-hydroxytryptamine receptor 1B | Homo sapiens (human) | 6.5 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0184 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0027 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0016 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.29 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 1.8 | |
Synaptic vesicular amine transporter | Homo sapiens (human) | 0.18 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.001 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baldanzi, G; Bertoni, A; Capello, D; Fresu, LG; Gesu, A; Graziani, A; Massarotti, A; Ruffo, E; Snow, AL; Talmon, M; Tron, GC; Varma, KSS; Velnati, S | 1 |
1 other study(ies) available for cochlioquinone a and ketanserin
Article | Year |
---|---|
Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
Topics: Cell Death; Computer Simulation; Diacylglycerol Kinase; Drug Evaluation, Preclinical; Humans; Lymphoproliferative Disorders; Piperidines; Protein Kinase Inhibitors; Pyrimidinones; Quinazolinones; Ritanserin; Thiazoles | 2019 |